The Chinese city of Tianjin has formally opened a dedicated Brain-Computer Interface Industrial Cluster, with the launch finalised on 29 May 2026 at the 2026 World Intelligence Expo (held 28-31 May) and detailed in China Daily reporting on 17 June 2026. The city has committed 100 million yuan (about $14.8 million at current rates) in dedicated annual funding to the cluster, has already incubated 22 BCI technology companies in the zone (China Daily figure; sister outlet ECNS reports “nearly 20” enterprises), and has set a goal of 50 competitive innovative enterprises by 2027. The cluster covers healthcare, education, advanced manufacturing, and a set of additional sectors China Daily does not enumerate specifically.
The institutional anatomy
The cluster’s foundational research arm is the Haihe Laboratory of Brain-Computer Interaction and Human-Machine Integration, which according to China Daily holds three world records in the BCI field and manages what state media characterise as the world’s largest patent portfolio in the category. The independent verifiability of those superlatives is limited to Chinese-language press, and the patent-portfolio claim should be read against the global BCI patent landscape rather than taken at face value. The Tianjin Brain-Computer Interface Industry Group operates as the operational umbrella for the cluster.
Clinical translation routes through Tianjin Huanhu Hospital and other top-tier hospitals, rehabilitation centres, and eldercare facilities in the city. The state-media framing is that Tianjin has built “an integrated innovation ecosystem linking research, industry, clinical trials and real-world deployment,” with hospitals acting as application bases rather than only trial sites.
What the 22 incubated companies cover
China Daily’s reporting describes the 22 incubated companies as spanning core electronic components, high-end chips, foundational software, and key underlying systems. The cluster framing is explicit about industrial supply-chain capability rather than only application-layer BCI development. One incubated example, Tiankai Suishi (Tianjin) Intelligent Technology Co, founded in 2023, has reportedly moved its BCI-based medical devices and treatment solutions into dozens of hospitals across more than 10 provincial-level regions in China.
Where this fits in the China BCI story
The Tianjin cluster sits inside a broader Chinese commercial scale-up cycle that has been building since the March 2026 NMPA approval of the Neuracle NEO implant, the first commercial invasive BCI clearance worldwide. Since then, China has issued guided pricing for invasive BCI procedures, opened the Order 818 parallel commercial pathway, and seen multi-company registration-trial activity including the StairMed WRS02 256-channel cortical interface and NeuCyber Beinao-1. The Tianjin cluster is the industrial-policy analogue to those market and regulatory moves: the same state framework that designated BCI as a five-year-plan priority is now committing fiscal and institutional capital to a specific city-based cluster.
The Industrial Builder posture, in the four-jurisdiction framing the field has been using to describe regulatory architectures (Rights-First Chile, Horizontal Regulator EU, State-Patchwork US, Industrial Builder China and South Korea), is now visible through dated infrastructure spending and named institutional commitments rather than only through policy announcements.
What the reporting does not address
China Daily’s coverage does not break out the 100 million yuan annual figure into its specific allocations across the cluster’s incubation, infrastructure, and clinical activities. It does not name any of the additional incubated companies beyond Tiankai Suishi. It does not address the cluster’s relationship with the established Chinese BCI cohort headquartered outside Tianjin (Neuracle in Changzhou, StairMed in Shanghai, BrainCo in Hangzhou, and NeuCyber). And it does not engage the export-control or foreign-investment posture that Order 818 and the 2024 Negative List Article 17 have placed around foreign-invested-enterprise access to the Chinese BCI commercial pathway.
What to watch
Three signals over the next two quarters. First, whether the Tianjin cluster’s incubated companies file for STAR Market or Hong Kong Stock Exchange listings in the way that BrainCo and Neuracle already have. Second, whether the 100 million yuan annual funding scales in subsequent fiscal-year announcements, or stays at the announced figure. Third, whether non-Chinese specialist trade press (FierceBiotech, MedTech Dive, Citeline) picks up the Tianjin cluster framing as the formal industrial-policy analogue to the commercial-rollout activity now visible in the Chinese BCI market. The story today is dated, specific, and primary-source-attributed. The story 12 months from now depends on which of those three signals comes through.
Sources
- Tianjin builds BCI innovation hub (China Daily Global Edition, 17 June 2026)
- Tianjin builds world-class brain-computer interface ecosystem (China Daily, 16 June 2026)
- Tianjin boosts status as BCI powerhouse (ecns.cn / China News Service, 16 June 2026)
- Mind Control: Tianjin’s world-class BCI (China Daily, 15 June 2026)
- China Prepares Tianjin as a Center for Brain-Computer Technology (VOI.id, Indonesia)
- China’s brain-computer interface industry is racing ahead (TechCrunch, February 2026 background)